HIV-1 virologic failure and acquired drug resistance among first-line antiretroviral experienced adults at a rural HIV clinic in coastal Kenya: A cross-sectional study

AIDS Research and Therapy

Volumn 11, Issue 1, 2014, Pages

  Hassan, Amin S ^a   Nabwera, Helen M ^a   Mwaringa, Shalton M ^a   Obonyo, Clare A ^b   Sanders, Eduard J ^a,c   Rinke de Wit, Tobias F ^d,e   Cane, Patricia A ^f   Berkley, James A ^a,c  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b Kilifi District Hospital   (Kenya)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d PharmAccess Foundation   (Netherlands)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

Acquired drug resistance; Correlates; HIV; Kenya; Rural; Virologic failure

Indexed keywords

EID: 84892686274     PISSN: None     EISSN: 17426405     Source Type: Journal    
DOI: 10.1186/1742-6405-11-9     Document Type: Article

References (42)

1. UNAIDS Core slides: Global summary of the AIDS epidemic 2012, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_epi_core_en.pdf]. Accessed 20 Nov 2012, UNAIDS.
2. UNAIDS Global AIDS epidemic facts and figures 2012, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/201207_FactSheet_Global_en.pdf]. Accessed 20 Nov 2012, UNAIDS.
3. NACC and NASCOP Kenya AIDS Epidemic update 2012, Available at: [http://www.unaids.org/en/dataanalysis/knowyourresponse/countryprogressreports/2012countries/ce_KE_Narrative_Report.pdf]. Accessed 04 April 2013, NACC and NASCOP.
4. Bendavid E, Bhattacharya J. The president's emergency plan for AIDS relief in Africa: an evaluation of outcomes. Ann Intern Med 2009, 150(10):688-695.
5. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reversal after introduction of antiretroviral therapy in Malawi. Lancet 2008, 371(9624):1603-1611.
6. UNAIDS World AIDS Day Report 2011, Available at: [http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/jc2216_worldaidsday_report_2011_en.pdf]. Accessed 20 Nov 2012, UNAIDS.
7. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009, 9(7):409-417.
8. Keiser O, Tweya H, Boulle A, et al. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. AIDS 2009, 23(14):1867-1874.
9. World Health Organization Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach - 2010 rev Available at: [http://whqlibdoc.who.int/publications/2010/9789241599764_eng.pdf]. Accessed 20 Nov 2012, World Health Organization.
10. Badri M, Lawn SD, Wood R. Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited setting. BMC Infect Dis 2008, 8:89.
11. Mee P, Fielding KL, Charalambous S, Churchyard GJ, Grant AD. Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa. AIDS 2008, 22(15):1971-1977.
12. van Oosterhout JJ, Brown L, Weigel R, et al. Diagnosis of antiretroviral therapy failure in Malawi: poor performance of clinical and immunological WHO criteria. Trop Med Int Health 2009, 14(8):856-861.
13. Barth RE, Tempelman HA, Moraba R, Hoepelman AI. Long-term outcome of an HIV-treatment programme in Rural Africa: viral suppression despite early mortality. AIDS Res Treat 2011, 2011:434375.
14. Kantor R, Diero L, Delong A, et al. Misclassification of first-line antiretroviral treatment failure based on immunological monitoring of HIV infection in resource-limited settings. Clin Infect Dis 2009, 49(3):454-462.
15. Barth RE, van der Loeff MF, Schuurman R, Hoepelman AI, Wensing AM. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010, 10(3):155-166.
16. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013, 18(1):115-123.
17. National AIDS & STI Control Programme Kenya National Clinical Manual For ART Providers Available at: [http://nascop.or.ke/library/ART%20guidelines/Kenya%20clinical%20National%20Manual%20for%20ART%20providers.pdf]. Accessed 20 Nov 2012, National AIDS & STI Control Programme.
18. Hassan AS, Fielding KL, Thuo NM, et al. Early loss to follow-up of recently diagnosed HIV-infected adults from routine pre-ART care in a rural district hospital in Kenya: a cohort study. Trop Med Int Health 2012, 17(1):82-93.
19. Goldman JD, Cantrell RA, Mulenga LB, et al. Simple adherence assessments to predict virologic failure among HIV-infected adults with discordant immunologic and clinical responses to antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24(8):1031-1035.
20. Weidle PJ, Wamai N, Solberg P, et al. Adherence to antiretroviral therapy in a home-based AIDS care programme in rural Uganda. Lancet 2006, 368(9547):1587-1594.
21. Cane P. HIV drug resistance testing. Methods Mol Biol 2011, 665:123-132.
22. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006, 42(11):1608-1618.
23. Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse transcriptase and protease sequence database. Nucleic Acids Res 2003, 31(1):298-303.
24. Kosakovsky Pond SL, Posada D, Stawiski E, et al. An evolutionary model-based algorithm for accurate phylogenetic breakpoint mapping and subtype prediction in HIV-1. PLoS Comput Biol 2009, 5(11):e1000581.
25. National aIDS & STI Control Program Guidelines for antiretroviral therapy in Kenya 2011, 4, [Available at: [http://healthservices.uonbi.ac.ke/sites/default/files/centraladmin/healthservices/Kenya%20Treatment%20Guidelines%202011.pdf]. Accessed 04 May 2013, National aIDS & STI Control Program.
26. Stadeli KM, Richman DD. Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review. Antivir Ther 2013, 18(1):115-123.
27. World Health Organization HIV Drug Resistance Early Warning Indicators. World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites June 2010 Update Available at: [http://www2.paho.org/hq/dmdocuments/2010/hivdr-early-warning-indicators-updated-april-2010.pdf]. Accessed 20 Nov 2012, World Health Organization.
28. Sigaloff KC, Hamers RL, Menke J, et al. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. Clin Infect Dis 2012, 54(Suppl 4):S294-S299.
29. El-Khatib Z, Katzenstein D, Marrone G, et al. Adherence to drug-refill is a useful early warning indicator of virologic and immunologic failure among HIV patients on first-line ART in South Africa. PLoS One 2011, 6(3):e17518.
30. Nachega JB, Hislop M, Dowdy DW, et al. Adherence to highly active antiretroviral therapy assessed by pharmacy claims predicts survival in HIV-infected South African adults. J Acquir Immune Defic Syndr 2006, 43(1):78-84.
31. Messou E, Chaix ML, Gabillard D, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr 2011, 56(4):356-364.
32. Dowshen N, D'Angelo L. Health care transition for youth living with HIV/AIDS. Pediatrics 2011, 128(4):762-771.
33. Assoumou L, Descamps D, Yerly S, et al. Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study. J Antimicrob Chemother 2013, 68(6):1400-1405.
34. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA 2005, 293(7):817-829.
35. Lee PK, Kieffer TL, Siliciano RF, Nettles RE. HIV-1 viral load blips are of limited clinical significance. J Antimicrob Chemother 2006, 57(5):803-805.
36. van Sighem A, Zhang S, Reiss P, et al. Immunologic, virologic, and clinical consequences of episodes of transient viremia during suppressive combination antiretroviral therapy. J Acquir Immune Defic Syndr 2008, 48(1):104-108.
37. Hamers RL, Wallis CL, Kityo C, et al. HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. Lancet Infect Dis 2011, 11(10):750-759.
38. Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012, 380(9849):1250-1258.
39. Hamers RL, Schuurman R, Sigaloff KC, et al. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. Lancet Infect Dis 2012, 12(4):307-317.
40. Kuritzkes DR, Lalama CM, Ribaudo HJ, et al. Preexisting resistance to nonnucleoside reverse-transcriptase inhibitors predicts virologic failure of an efavirenz-based regimen in treatment-naive HIV-1-infected subjects. J Infect Dis 2008, 197(6):867-870.
41. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011, 11(5):363-371.
42. Hassan AS, Mwaringa SM, Obonyo CA, et al. Low prevalence of transmitted HIV type 1 drug resistance among antiretroviral-naive adults in a Rural HIV clinic in Kenya. AIDS Res Hum Retroviruses 2013, 29(1):129-135.